AUTHORS
Brenda Sofia Castillo, MD, Mazyar Shadman, MD, MPH2, Mary W Redman, PhD3, Kelsey K Baker4, Sang Yun K Lee5, Cecilia CS Yeung, MD, Professor Pathology6, Kikkeri N Naresh, MD, MBBS, FRCPath7, Folashade Otegbeye, MBBChir,MPH8, Dong Hoon Lee9, David Woolston10, David H Qian11, Xiaoling Song, PhD12, Bruce Dezube, MD13, Manuel Litchman, MD14, Stephen Smith, MD15, Ajay Gopal, MD16, Ryan C Lynch, MD17, Edus H. Warren, MD, PhD18, Jonathan R Fromm, MD, PhD19, Aude Chapuis, MD20, Ryan D. Cassaday, MD21, Hans-Peter Kiem, PhD22, Filippo Milano I, MD, PhD23, Lorenzo Iovino, MD, PhD24, Alexandre V Hirayama, MD25, Jordan Gauthier, MD26, David G Maloney, MD, PhD27, Brian G Till, MD28
AFFILIATIONS
1 University of Washington/Fred Hutch Cancer Center, Seattle, Washington, United States
2 University of Washington/Fred Hutch Cancer Center, Seattle, Washington, United States
3 Fred Hutch Cancer Center, Seattle, United States
4 Fred Hutch Cancer Center, Seattle, United States
5 Fred Hutch Cancer Center, Seattle, United States
6 University of Washington/Fred Hutch Cancer Center, Seattle, Washington, United States
7 University of Washington/Fred Hutch Cancer Center, Seattle, Washington, United States
8 University of Washington/Fred Hutch Cancer Center, Seattle, Washington, United States
9 Fred Hutch Cancer Center, Seattle, United States
10 Fred Hutch Cancer Center, Seattle, United States
11 Fred Hutch Cancer Center, Seattle, United States
12 Fred Hutch Cancer Center, Seattle, United States
13 Musang Bio, Waltham, Massachusetts, United States
14 Musang Bio, Waltham, Massachusetts, United States
15 University of Washington/Fred Hutch Cancer Center, Seattle, Washington, United States
16 University of Washington/Fred Hutch Cancer Center, Seattle, Washington, United States
17 University of Washington/Fred Hutch Cancer Center, Seattle, Washington, United States
18 University of Washington/Fred Hutch Cancer Center, Seattle, Washington, United States
19 University of Washington/Fred Hutch Cancer Center, Seattle, Washington, United States
20 University of Washington/Fred Hutch Cancer Center, Seattle, Washington, United States
21 University of Washington/Fred Hutch Cancer Center, Seattle, Washington, United States
22 University of Washington/Fred Hutch Cancer Center, Seattle, Washington, United States
23 University of Washington/Fred Hutch Cancer Center, Seattle, Washington, United States
24 University of Washington/Fred Hutch Cancer Center, Seattle, Washington, United States
25 University of Washington/Fred Hutch Cancer Center, Seattle, Washington, United States
26 University of Washington/Fred Hutch Cancer Center, Seattle, Washington, United States
27 University of Washington/Fred Hutch Cancer Center, Seattle, Washington, United States
28 University of Washington/Fred Hutch Cancer Center, Seattle, Washington, United States
ABSTRACT
Introduction: Follicular lymphoma (FL) is an indolent B-cell lymphoma, often considered incurable. Though there are several treatment (tx) options for relapsed/refractory (R/R) disease, there are no approved CD20-targeted chimeric antigen receptor T-cell (CAR-T) therapies for FL. We evaluated the safety and efficacy of an autologous CD20-targeted CAR-T product in a cohort of 20 patients with R/R FL as part of a larger phase 1/2 trial (NCT03277729).
Methods: Eligible patients (pts) were ≥18 years of age with histologically confirmed CD20+ FL, relapsed after a response to at least one line of therapy or refractory to prior tx. Prior tx with CD19-targeted CAR-T was permitted. Lymphodepletion (LD) consisted of cyclophosphamide and fludarabine. CAR T cells were administered at one of four dose levels (DL): 3.3 x 105, 1 x 106, 3.3 x 106, or 1 x 107 CAR T cells/kg. In the larger trial, a continual reassessment method targeting a dose-limiting toxicity (DLT) rate of 25% was used to assign patients to doses, model the relationship between DL and the probability of DLT, and estimate the maximum tolerated dose, which will be reported separately. Initial treatment response for the FL cohort was assessed on day 28 and best response is reported here. Cytokine release syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) were graded per ASTCT criteria.
Results: Between Dec. 2019 and Nov. 2022, 20 pts were treated and all were response-evaluable. The median age was 62.8 (range 45-81), and 9 (45%) pts were ≥65 years old. Twelve (60%) pts were female. Eighteen (90%) were White. Pts were high-risk and heavily pre-treated, with a median of 4 (range 1-12) prior lines of tx. Thirteen (65%) pts had prior progression of disease within 24 months (POD24), 65% had bulky disease (> 5 cm) and 65% had high-risk disease by FLIPI at baseline. All pts received previous anti-CD20 monoclonal antibody combined with an alkylating agent-based regimen; 16 (80%) patients had received anthracyclines, 9 (45%) lenalidomide, 2 (10%) prior autologous stem cell transplant, and 1 (5%) prior CD19 CAR-T. The median times from leukapheresis to LD and to CAR-T infusion were 10 days (range, 5-23) and 15 days (range, 10-28), respectively. Five (25%) pts received bridging therapy: lenalidomide (n=2), methylprednisolone and lenalidomide (n=1), bendamustine (n=1), and prednisone (n=1). The median CAR T-cell dose infused was 3.3 x 106 CAR T cells/kg (DL3) (range 1.36 x 105 to 9.77 x 106 CAR T cells/kg). CRS occurred in 6 pts (30%), 5 with grade (Gr) 1 and one with Gr 2. No pts had Gr ≥3 CRS and none had ICANS. In the first 28 days, 15 (75%) pts experienced Gr 4 lymphopenia, 13 (65%) Gr 4 neutropenia, two (10%) Gr 4 thrombocytopenia, and three (5%) Gr 3 anemia. The rate of febrile neutropenia was 15%. One pt had Gr 3 infection (pneumonia and bacteremia), 1 Gr 3 venous thromboembolism, and 1 Gr 3 rash (Drug Reaction with Eosinophilia and Systemic Symptoms syndrome of unclear cause). Overall response rate (ORR) was 95%, with a best response of complete response (CR) in 80% of pts. There have been 9 (45%) progression events and 5 (25%) deaths. The cause of death was PD for 3(15%) pts. Two pts died in CR: one late death due to COVID-19 and one due to myelodysplastic syndrome (MDS). Another pt had long-term cytopenias and was diagnosed with tx-related MDS at 3.7 years post-tx. Except for a late relapse at 3 years post-treatment in one pt, relapses occurred early (median 3.5 months post-tx, range 1.1 – 10.1). Of the 13 (65%) pts in CR at 1-year post-tx, 10 (77%) remain alive and 8 (61%) remain in remission. With a median follow-up of 48.6 months (range 33.2 – 64.2) among surviving patients, the 3-year estimates (95% confidence interval) of progression-free survival (PFS) and overall survival (OS) are 44% (22%, 64%) and 75% (49%, 89%), respectively.
Conclusion: In this cohort of high-risk, heavily pre-treated pts with FL, CD20-targeted CAR-T had a favorable safety profile and high ORR and CR rates with durable remissions. In contrast to approved CD19-targeted CAR-T products for FL, no ICANS or severe CRS were observed. These findings should be interpreted with caution due to a small sample size and limitations of cross-trial comparisons. The use of CD20-targeted CAR-T should be investigated further, as this could represent another therapeutic option, particularly in pts who progress after CD19-targeted CAR-T.
DISCLOSURES
Brenda Sofia Castillo, MD: No relevant conflicts of interest to declare.